Bupivacaine
- PDF / 169,593 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 96 Downloads / 181 Views
1 S
Bupivacaine Numbness and urinary retention following intrathecal administration (i.e. off-label administration) of bupivacaine: 7 case reports
In a retrospective study of 163 patients who received bupivacaine via intrathecal pump between mid-2017 and mid-2019 at Memorial Sloan Kettering Cancer Center, USA, 7 patients [ages and sexes not stated] were described, who developed numbness or urinary retention following intrathecal administration (i.e. off-label route of drug administration) of bupivacaine for refractory caner pain [durations of treatments to reactions onsets and outcomes not stated]. The patients, who had refractory caner pain, received bupivacaine 10 mg/day bolus at a concentration of 40 mg/mL via intrathecal pump at Memorial Sloan Kettering Cancer Center. The intrathecal administration of bupivacaine was considered as off-label route of drug administration. The patient’s concomitant medication included an unspecified opioid. The patients subsequently developed urinary retention (3 patients) and numbness (4 patients). Of these 7 patients, bupivacaine dose was decreased to 4–9 mg/day in 4 patients at the time of discharge, bupivacaine was stopped in one patient at the time of discharge, one patient was discharged at the same bupivacaine dose (i.e. at 10 mg/day) and one patient was discharged at a slightly higher bupivacaine dose of 10.5 mg/day. Chen GH, et al. Evaluation of Fixed Intrathecal Bupivacaine Infusion Doses in the Oncologic Population. Neuromodulation 23: 984-990, No. 7, Oct 2020. Available from: 803518121 URL: http://doi.org/10.1111/ner.13161
0114-9954/20/1832-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 28 Nov 2020 No. 1832
Data Loading...
